ReviewCurrent opinion in immunology2010
Targeting BAFF in autoimmunity.
Review in Current opinion in immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 105 citations in OpenAlex.
- Expansion of inflammatory monocytes in periphery and infiltrated into thyroid tissue in Graves' disease.Scientific reports · 2021Trial
- Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.British journal of clinical pharmacology · 2016Trial
- Gd-IgA1-targeting therapy in IgA nephropathy ~what is pathogenic Gd-IgA1?~.Frontiers in nephrology · 2026Review
- The path less traveled: the non-canonical NF-κB pathway in systemic lupus erythematosus.Frontiers in immunology · 2025Review
- BAFF and APRIL immunotherapy following Bacille Calmette-Guérin vaccination enhances protection against pulmonary tuberculosis in mice.Frontiers in immunology · 2025Article
- Integrated proteomic and transcriptomic landscape of human placenta in small for gestational age infants.iScience · 2024Article
- Development and Characterization of a Novel Single-Chain Antibody Against B-Cell Activating Factor.Molecular biotechnology · 2023Article
- Article
- Dysregulated MicroRNAs in the Pathogenesis of Systemic Lupus Erythematosus: A Comprehensive Review.International journal of biological sciences · 2023Review
- New Targeted Agents in Myasthenia Gravis and Future Therapeutic Strategies.Journal of clinical medicine · 2022Review
- Evaluating the Link between BAFF System Gene Expression and Acute Rejection Development in Kidney Transplantation.Journal of clinical medicine · 2022Article
- Systemic Lupus Erythematosus-Associated Serositis Managed With Intravenous Belimumab: A Case Report.Cureus · 2022Article
- A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers.Nature communications · 2022Article
- Serum markers of B-cell activation in pregnant women with atopic asthma.American journal of reproductive immunology (New York, N.Y. : 1989) · 2021Observational
- Role of biomarkers in the diagnosis and prognosis of patients with cutaneous lupus erythematosus.Annals of translational medicine · 2021Review
- The effects of BAFF on T lymphocytes in chronic obstructive pulmonary disease.Respiratory research · 2020Article
- CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.Science translational medicine · 2019Article
- Serum markers of B-cell activation in pregnancy during late gestation, delivery, and the postpartum period.American journal of reproductive immunology (New York, N.Y. : 1989) · 2019Article
- Curcumin attenuates lupus nephritis in MRL/lpr mice by suppressing macrophage-secreted B cell activating factor (BAFF).International journal of clinical and experimental pathology · 2019Article
- Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients.JCI insight · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
BAFF and APRIL are TNF-like cytokines that support survival and differentiation of B cells. The early appreciation that overexpression of BAFF leads to B cell expansion and a lupus-like syndrome in mice, and the demonstration that BAFF inhibition delays lupus onset in spontaneous mouse models of SLE and other autoimmune diseases has rapidly led to the development of strategies for inhibiting both BAFF and APRIL. The commercialization of this new class of drugs has proceeded in parallel with the continuing elucidation of the biology of the cytokines and their receptors. Recent studies have uncovered a role for BAFF in enhancing both innate and adaptive immune responses and in amplifying aberrant pathways that arise during inflammation. Two phase III studies of an anti-BAFF antibody have yielded positive, although modest, results in SLE and alternate inhibitors are being tested in a variety of autoimmune diseases in which BAFF may play a pathogenic role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.